NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix announces four presentations at the Society for Immunotherapy of Cancer (SITC) 35th anniversary annual meeting
    Nanobiotix announces first patient injected with NBTXR3 in pancreatic cancer and safe to proceed notifications for two additional trials from U.S. FDA
    Nanobiotix receives feedback from US FDA to advance phase III head and neck cancer study design and CMC development plan for NDA

    ALL NANOBIOTIX PRESS RELEASES

    Events

    October 19-20, 2020

    CF&B EUROPEAN MIDCAP EVENT

    More info
    October 25-28, 2020

    ASTRO 2020

    More info

    JOIN US


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer
     

    Download our latest
    Corporate Presentation

     
    English